Development of vector molecules for CNS delivery of ECM drug and imaging candidates developed by partners

 

 

Some of the candidate anti-epileptic drugs (AEDs) and radiotracers to be developed within the project will be biomolecules, notably peptides. Peptides were generally considered to be bad drug candidates because of their poor pharmacokinetics. New synthetic strategies to improve productivity and reduce metabolism of peptides, along with alternative routes of administration have been developed in recent years, and a large number of peptide-based drugs are now being marketed. However, while biomolecules, including peptides can be developed as efficient drug candidates, this class of molecules crosses poorly the blood brain barrier (BBB). Hence, BBB technology is paramount to efficient CNS delivery of bio-molecules. In this project, we aim (1) to further characterize the vector-drug conjugate generated and patented by AMU and Vect-Horus that has anti-convulsive/anti inflammatory and neuroprotective properties in an animal model of epilepsy; (2) to conjugate the AED drug candidates and peptide-based radiotracers generated within the project that cross poorly the BBB, to peptide vectors in order to enhance their delivery into the brain.

 

 

Supervisor: Dr Michel Khrestchatisky (or someone with similar expertise)

 

To apply :

send a CV, a copy of higher education diploma, a list of completed subjects and grades achieved, and a motivation letter stating research interests and indicating the first and second choice among ECMED partners to Dr. Michel Khrestchatisky